Sonnet BioTherapeutics Holding (SONN US)

Sonnet BioTherapeutics Holdings, Inc. operates as a clinical stage biotechnology company. The Company develops fully human albumin binding technology that helps the development of innovative targeted biologic drugs with enhanced single-or bi-specific mechanisms. Sonnet BioTherapeutics Holdings serves customers in the United States.